FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

RegulatoryibezapolstatPositive

AI Analysis

Summary

Acurx Pharmaceuticals received FDA guidance supporting a single Phase 3 trial design for ibezapolstat to treat and reduce recurrence of C. difficile infection, with potential for NDA submission based on this pathway.

Clinical Trial Data

Phase

Phase 3

Outcome Details

FDA guidance provided for Phase 3 clinical program with potential for single-phase 3-trial registration plan

Importance:7/10

Sentiment:

0.70

FDA guidanceType C MeetingNDA pathwayibezapolstatC. difficilesingle Phase 3 trialregulatory milestone

Read the original article

Published by PR Newswire Biotech on August 3, 2026 12:00 PM

Read Original